Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity

Next Previous
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WVE 007 (Primary)
  • Indications Obesity; Overweight
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms INLIGHT
  • Sponsors WaVe life Sciences

Most Recent Events

  • 30 Jul 2025 According to a Wave Life Sciences media release, company expects to deliver data from the expanded Cohort 2 (240 mg) as well as data from Cohort 1 (75mg) of INLIGHT in the fourth quarter of 2025, including safety, tolerability and measurements reflective of healthy weight loss.
  • 30 Jul 2025 According to a Wave Life Sciences media release, Dosing is also underway in Cohort 3 (400 mg) with data anticipated in the first quarter of 2026.
  • 08 May 2025 According to a Wave Life Sciences media release, dosing complete in the first two cohorts of this trial in obesity and expects to deliver clinical data in second half of 2025, including safety, tolerability and biomarkers reflective of healthy weight loss.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top